stugeron 25 mg tabletes
gedeon richter plc., hungary - cinnarizīns - tablete - 25 mg
geroxynal 5 mg/2,5 mg ilgstošās darbības tabletes
g.l. pharma gmbh, austria - oxycodoni hydrochloridum, naloxoni hydrochloridum - ilgstošās darbības tablete - 5 mg/2,5 mg
geroxynal 30 mg/15 mg ilgstošās darbības tabletes
g.l. pharma gmbh, austria - oxycodoni hydrochloridum, naloxoni hydrochloridum - ilgstošās darbības tablete - 30 mg/15 mg
geroxynal 20 mg/10 mg ilgstošās darbības tabletes
g.l. pharma gmbh, austria - oxycodoni hydrochloridum, naloxoni hydrochloridum - ilgstošās darbības tablete - 20 mg/10 mg
geroxynal 40 mg/20 mg ilgstošās darbības tabletes
g.l. pharma gmbh, austria - oxycodoni hydrochloridum, naloxoni hydrochloridum - ilgstošās darbības tablete - 40 mg/20 mg
geroxynal 10 mg/5 mg ilgstošās darbības tabletes
g.l. pharma gmbh, austria - oxycodoni hydrochloridum, naloxoni hydrochloridum - ilgstošās darbības tablete - 10 mg/5 mg
stugeron 25 mg tabletes
johnson & johnson, uab, lithuania - cinnarizīns - tablete - 25 mg
bleomycin medac 15000 sv pulveris injekciju šķīduma pagatavošanai
medac gesellschaft für klinische spezialpräparate mbh, germany - bleomicīna sulfāts - pulveris injekciju šķīduma pagatavošanai - 15000 sv
bleomycin medac 30000 sv pulveris injekciju šķīduma pagatavošanai
medac gesellschaft für klinische spezialpräparate mbh, germany - bleomicīna sulfāts - pulveris injekciju šķīduma pagatavošanai - 30000 sv
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - karmustīns - hodgkin disease; lymphoma, non-hodgkin - antineoplastiski līdzekļi - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).